Post CAR ‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70343 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Snegha Ananth und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Immunotherapy, Adoptive. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR‐T surveillance and consolidation strategies. Measurable residual disease (MRD) has emerged as a powerful prognostic biomarker in frontline MCL, but its role after CAR T‐cell therapy remains incompletely defined. We retrospectively analyzed 37 patients with r/r MCL treated with brexucabtagene autoleucel (brexu‐cel). MRD was assessed using next‐generation immunoglobulin high‐throughput sequencing (Ig‐HTS) of peripheral blood mononuclear cells obtained before lymphodepletion, at 1‐ and 3‐months post‐infusion, and every 3 months thereafter. Clonotype identification was successful in 36 of 37 patients. Pre‐lymphodepletion MRD levels were lower in patients receiving bridging therapy (337 [0–198 449] vs. 21 213 [1–788 251]; p = 0.04), and MRD undetectability trended toward improved progression‐free survival (PFS; unreached vs. 28.5 months; HR 5.2; p = 0.07). Post‐infusion, patients with detectable Day 28 MRD had inferior PFS compared with those with undetectable MRD (10.9 vs. 51.5 months; HR 3.99; p = 0.002), whereas Day 28 PET‐CT response did not correlate with PFS ( p = 0.35; HR 1.8). Longitudinal MRD monitoring identified relapse a median of 6.5 months before PET/CT in most relapsing patients (15 out of 18). Early and serial MRD monitoring is thus a sensitive prognostic and surveillance tool in brexu‐cel treated MCL, with Day 28 MRD serving as an early predictor of long‐term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, California, USA.
- University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Adaptive Biotechnologies, Seattle, Washington, USA.
ORCID-Profile: Snegha Ananth, Allison Jacob
Zitieren
APA
Ananth, S., Agarwal, N., Sahaf, B., Jacob, A., Lee, L. W., Simmons, H., Kirsch, I., Bharadwaj, S., Weng, W. K., Smith, M., Dahiya, S., Miklos, D., & Frank, M. J. (2026). Post CAR ‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse. American Journal of Hematology. https://doi.org/10.1002/ajh.70343
Vancouver
Ananth S, Agarwal N, Sahaf B, Jacob A, Lee LW, Simmons H, et al. Post CAR ‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse. American Journal of Hematology. 2026. doi:10.1002/ajh.70343
BibTeX
@article{Ananth2026,
author = {Ananth, Snegha and Agarwal, Neha and Sahaf, Bita and Jacob, Allison and Lee, Lik Wee and Simmons, Heidi and Kirsch, Ilan and Bharadwaj, Sushma and Weng, Wen-Kai and Smith, Melody and Dahiya, Saurabh and Miklos, David and Frank, Matthew J},
title = {Post CAR ‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70343}
}
EUVIMED